A Kyoto University spinout company having production technologies to generate high performance artificial blood cells from stem cells. Their Mylc cell series are highly controlled immature dendritic cells suitable for evaluation of efficacy of drug discovery and safety assessment. Recently launched cMylc kit is exclusively designed for COVID-19 vaccines and drug development. The coronavirus optimised optimized myeloid lineage cells works as host cells with giving stable and robust performances for your research on COVID-19.
